These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

804 related articles for article (PubMed ID: 33786454)

  • 1. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.
    Avouac J; Drumez E; Hachulla E; Seror R; Georgin-Lavialle S; El Mahou S; Pertuiset E; Pham T; Marotte H; Servettaz A; Domont F; Chazerain P; Devaux M; Claudepierre P; Langlois V; Mekinian A; Maria ATJ; Banneville B; Fautrel B; Pouchot J; Thomas T; Flipo RM; Richez C; ;
    Lancet Rheumatol; 2021 Jun; 3(6):e419-e426. PubMed ID: 33786454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients.
    FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors
    Ann Rheum Dis; 2021 Apr; 80(4):527-538. PubMed ID: 33268442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study.
    Fredi M; Cavazzana I; Moschetti L; Andreoli L; Franceschini F;
    Lancet Rheumatol; 2020 Sep; 2(9):e549-e556. PubMed ID: 32838307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 presentation and outcomes in patients with inflammatory rheumatic and musculoskeletal diseases receiving IL6-receptor antagonists prior to SARS-CoV-2 infection.
    Comarmond C; Drumez E; Labreuche J; Hachulla E; Thomas T; Flipo RM; Seror R; Avouac J; Balandraud N; Desbarbieux R; Felten R; Gilson M; Guyot MH; Hittinger-Roux A; Pham T; Renard M; Roux N; Sobanski V; Tournadre A; Richez C; Cacoub P;
    J Transl Autoimmun; 2023; 6():100190. PubMed ID: 36684808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases.
    Chevalier K; Genin M; Jean TP; Avouac J; Flipo RM; Georgin-Lavialle S; El Mahou S; Pertuiset E; Pham T; Servettaz A; Marotte H; Domont F; Chazerain P; Devaux M; Mekinian A; Sellam J; Fautrel B; Rouzaud D; Ebstein E; Costedoat-Chalumeau N; Richez C; Hachulla E; Mariette X; Seror R
    Front Med (Lausanne); 2023; 10():1152587. PubMed ID: 37035330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.
    Loarce-Martos J; García-Fernández A; López-Gutiérrez F; García-García V; Calvo-Sanz L; Del Bosque-Granero I; Terán-Tinedo MA; Boteanu A; Bachiller-Corral J; Vázquez-Díaz M
    Rheumatol Int; 2020 Dec; 40(12):2015-2021. PubMed ID: 32945944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of COVID-19 in patients with rheumatic and inflammatory diseases treated with mycophenolic acid: data from the French RMD COVID-19 cohort.
    Truchetet ME; Drumez E; Barnetche T; Martin C; Devaux M; Goulenok T; Maria A; Schmidt J; Abdallah NA; Melki I; Hachulla E; Richez C
    RMD Open; 2022 Sep; 8(2):. PubMed ID: 36113962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study.
    Shin YH; Shin JI; Moon SY; Jin HY; Kim SY; Yang JM; Cho SH; Kim S; Lee M; Park Y; Kim MS; Won HH; Hong SH; Kronbichler A; Koyanagi A; Jacob L; Smith L; Lee KH; Suh DI; Lee SW; Yon DK
    Lancet Rheumatol; 2021 Oct; 3(10):e698-e706. PubMed ID: 34179832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform.
    MacKenna B; Kennedy NA; Mehrkar A; Rowan A; Galloway J; Matthewman J; Mansfield KE; Bechman K; Yates M; Brown J; Schultze A; Norton S; Walker AJ; Morton CE; Harrison D; Bhaskaran K; Rentsch CT; Williamson E; Croker R; Bacon S; Hickman G; Ward T; Davy S; Green A; Fisher L; Hulme W; Bates C; Curtis HJ; Tazare J; Eggo RM; Evans D; Inglesby P; Cockburn J; McDonald HI; Tomlinson LA; Mathur R; Wong AYS; Forbes H; Parry J; Hester F; Harper S; Douglas IJ; Smeeth L; Lees CW; Evans SJW; Goldacre B; Smith CH; Langan SM
    Lancet Rheumatol; 2022 Jul; 4(7):e490-e506. PubMed ID: 35698725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of COVID-19 severity and outcomes in Indian patients with rheumatic diseases: a prospective cohort study.
    Mathew J; Jain S; Susngi T; Naidu S; Dhir V; Sharma A; Jain S; Sharma SK
    Rheumatol Adv Pract; 2023; 7(1):rkad025. PubMed ID: 36908302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study.
    Jorge A; D'Silva KM; Cohen A; Wallace ZS; McCormick N; Zhang Y; Choi HK
    Lancet Rheumatol; 2021 Feb; 3(2):e131-e137. PubMed ID: 33392516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD.
    Regierer AC; Hasseli R; Schäfer M; Hoyer BF; Krause A; Lorenz HM; Pfeil A; Richter J; Schmeiser T; Schulze-Koops H; Strangfeld A; Voll RE; Specker C; Mueller-Ladner U
    RMD Open; 2021 Oct; 7(3):. PubMed ID: 34670840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with COVID-19 severity in patients with spondyloarthritis: Results of the French RMD COVID-19 cohort.
    Perrot L; Boyer L; Flipo RM; Marotte H; Pertuiset E; Miceli C; Thomas T; Seror R; Chazerain P; Roux N; Richez C; Pham T;
    Joint Bone Spine; 2023 Dec; 90(6):105608. PubMed ID: 37414137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of COVID-19 in Inflammatory Rheumatic Diseases: A Retrospective Cohort Study.
    Alhowaish TS; Alhamadh MS; Alhabeeb AY; Aldosari SF; Masuadi E; Alrashid A
    Cureus; 2022 Jun; 14(6):e26343. PubMed ID: 35903564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases.
    Hasseli R; Mueller-Ladner U; Hoyer BF; Krause A; Lorenz HM; Pfeil A; Richter J; Schäfer M; Schmeiser T; Strangfeld A; Schulze-Koops H; Voll RE; Specker C; Regierer AC
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33479021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
    Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study.
    Hsu TY; D'Silva KM; Patel NJ; Wang J; Mueller AA; Fu X; Prisco L; Martin L; Vanni KMM; Zaccardelli A; Cook C; Choi HK; Zhang Y; Gravallese EM; Wallace ZS; Sparks JA
    Lancet Rheumatol; 2021 Sep; 3(9):e638-e647. PubMed ID: 34095857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study.
    Gao M; Piernas C; Astbury NM; Hippisley-Cox J; O'Rahilly S; Aveyard P; Jebb SA
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):350-359. PubMed ID: 33932335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.